Business Context and Reporting Period
This Form 8-K Current Report was filed by BeiGene, Ltd. (not Beone Medicines Ltd.) on September 26, 2024, reporting events occurring on September 25, 2024. The filing announces a change in the composition of the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation.
Material Changes
- Board Expansion: The Board of Directors increased its size from 11 to 12 members.
- New Appointment: Shalini Sharp was appointed as a Class III Director, effective September 27, 2024, serving until the 2025 annual meeting.
- Committee Assignment: Ms. Sharp was appointed to the Audit Committee.
Management Commentary and Compensation
Management cited Ms. Sharp's significant management experience in the healthcare sector and deep financial expertise as key qualifications. Her background includes serving as CFO for Ultragenyx Pharmaceuticals and Agenus Inc., and board service for Neurocrine Biosciences and Organon & Co.
Compensation Package for Ms. Sharp:
- Equity Awards: Valued at US$400,000 (pro-rated for the first year), consisting of share options and RSUs vesting on the first anniversary or the next annual meeting.
- Cash Compensation: US$65,000 annually for Board service and US$17,500 annually for Audit Committee service (both pro-rated for the first year).
- Other: Reimbursement for reasonable travel and expenses.
Investor Verification Checklist
- Verify the correct registrant name is BeiGene, Ltd. (Ticker: BGNE), not Beone Medicines Ltd.
- Confirm the effective date of the new director's appointment is September 27, 2024.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Note that this filing contains no financial results; refer to recent 10-Q or 10-K filings for financial metrics.